Abstract
Current guidelines emphasize the prevention of cardiovascular disease through lifestyle interventions and lipid-lowering therapies. Specifically, treatment goals for LDL-C reduction tend to be more stringent. The 2019 guidelines on dyslipidemia of the European Society of Cardiology/European Atherosclerosis Society proposed LDL-C goals of <55, <100, and <116 mg/dL for high-, moderate-, and low-risk patients, respectively. The updated approach for cardiovascular disease is to use cholesterol-lowering therapies safely and effectively to achieve lower LDL-C targets and reduce cardiovascular risk.